EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Atezolizumab plus Chemotherapie mit oder ohne Bevacizumab bei fortgeschrittenem biliärem Traktkarzinom: klinische und Biomarker-Daten aus der randomisierten Phase-II-Studie IMbrave151

Teresa Macarulla iD, Zhenggang Ren, Hong Jae Chon iD, Joon Oh Park iD, Jin Won Kim, Tiziana Pressiani iD, Daneng Li iD, Lyudmila Zhukova, Andrew X Zhu iD, Ming-Huang Chen iD, Stephen P Hack iD, Stephanie Wu iD und 5 weitere

Journal of Clinical Oncology · 10.02.2025 · 43 (5) · 545-557

DOI: 10.1200/jco.24.00337 ↗

Auf einen Blick

Bei 162 Patient:innen mit zuvor unbehandeltem fortgeschrittenem biliärem Traktkarzinom verlängerte Bevacizumab zusätzlich zu Atezolizumab plus CisGem das progressionsfreie Überleben leicht. Das Gesamtüberleben unterschied sich nicht.

Fragestellung

Verbessert Bevacizumab zusätzlich zu Atezolizumab plus Cisplatin/Gemcitabin bei fortgeschrittenem biliärem Traktkarzinom das progressionsfreie Überleben?

Methode

Randomisierte, doppelblinde, proof-of-concept Phase-II-Studie; 1:1-Zuteilung zu Atezolizumab plus Bevacizumab oder Placebo, jeweils mit Cisplatin/Gemcitabin; Biomarkeranalyse an Basistumoren.

Ergebnisse

162 Patient:innen. Medianes PFS: 8,3 Monate vs. 7,9 Monate; HR 0,67 (95 %-KI 0,46–0,95). Medianes OS: 14,9 vs. 14,6 Monate; HR 0,97 (95 %-KI 0,64–1,47). Grad 3/4 AE: 74 % in beiden Armen.

Einschränkungen

Keine formale Hypothesentestung. Explorative Biomarkeranalysen nur in Teilgruppen mit 95 bzw. 102 Proben.

Schlussfolgerung der Autor:innen

Bei unselektierten Patient:innen mit fortgeschrittenem BTC verbessert Bevacizumab zusätzlich zu Atezolizumab plus CisGem das PFS mäßig, nicht aber das OS. Hohes VEGFA kann ein prädiktiver Biomarker sein.

Kernaussagen

  • PFS: 8,3 Monate mit Bevacizumab vs. 7,9 Monate mit Placebo
  • OS: 14,9 vs. 14,6 Monate; kein Vorteil für Bevacizumab
  • Hohe VEGFA-Expression war mit besserem PFS im Bevacizumab-Arm assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2025. Verfasst von Teresa Macarulla und 16 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain. Hauptthemen laut MEDLINE: Bevacizumab, Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Biliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti–vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response to PD-L1 inhibition. PATIENTS AND METHODS This randomized, double-blind, proof-of-concept phase II study enrolled patients (n = 162) with previously untreated advanced BTC (IMbrave151; ClinicalTrials.gov identifier: NCT04677504 ). Patients were randomly assigned 1:1 to receive cycles of atezolizumab (1,200 mg) plus bevacizumab (15 mg/kg) or atezolizumab plus placebo once every 3 weeks until disease progression or unacceptable toxicity. All patients received cisplatin (25 mg/m 2 ) plus gemcitabine (1,000 mg/m 2 ; cisplatin plus gemcitabine [CisGem]) on days 1 and 8 once every 3 weeks for up to eight cycles. Stratification of patients was by disease status, geographic region, and primary tumor location. The primary end point was progression-free survival (PFS). No formal hypothesis testing was performed. Exploratory correlative biomarker analysis was undertaken using transcriptome analysis (n = 95) and mutation profiling (n = 102) on baseline tumor samples. RESULTS Between February and September 2021, 162 patients were enrolled. Median PFS was 8.3 months in the bevacizumab arm and 7.9 months in the placebo arm (stratified hazard ratio [HR], 0.67 [95% CI, 0.46 to 0.95]). Median overall survival (OS) was 14.9 and 14.6 months in the bevacizumab and placebo arms, respectively (stratified HR, 0.97 [95% CI, 0.64 to 1.47]). The incidence of grade 3 or 4 adverse events was 74% in both arms. High VEGFA gene expression was associated with improved PFS (HR, 0.44 [95% CI, 0.23 to 0.83]) in the bevacizumab arm versus placebo. CONCLUSION In unselected patients with advanced BTC, adding bevacizumab to atezolizumab plus CisGem modestly improves PFS but not OS. High VEGFA gene expression may represent a predictive biomarker of benefit from atezolizumab/bevacizumab, warranting further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabBiliary Tract NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodAdultDeoxycytidineCisplatinGemcitabineProgression-Free Survival

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, HumanizedBiomarkers, TumorDeoxycytidineCisplatinGemcitabine

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain.
  • Department of Hepatic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • CHA Bundang Medical Center, Seongnam-Si, South Korea.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.

ORCID-Profile: Teresa Macarulla, Hong Jae Chon, Joon Oh Park, Tiziana Pressiani, Daneng Li, Andrew X Zhu, Ming-Huang Chen, Stephen P Hack, Stephanie Wu, Yulei Wang, Anthony B El-Khoueiry

Zitieren

APA

Macarulla, T., Ren, Z., Chon, H. J., Park, J. O., Kim, J. W., Pressiani, T., Li, D., Zhukova, L., Zhu, A. X., Chen, M. H., Hack, S. P., Wu, S., Liu, B., Guan, X., Lu, S., Wang, Y., & El-Khoueiry, A. B. (2025). Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. Journal of Clinical Oncology, 43(5), 545-557. https://doi.org/10.1200/jco.24.00337

Vancouver

Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, et al. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. Journal of Clinical Oncology. 2025;43(5):545-557. doi:10.1200/jco.24.00337

BibTeX
@article{Macarulla2025,
  author = {Macarulla, Teresa and Ren, Zhenggang and Chon, Hong Jae and Park, Joon Oh and Kim, Jin Won and Pressiani, Tiziana and Li, Daneng and Zhukova, Lyudmila and Zhu, Andrew X and Chen, Ming-Huang and Hack, Stephen P and Wu, Stephanie and Liu, Bo and Guan, Xiangnan and Lu, Shan and Wang, Yulei and El-Khoueiry, Anthony B},
  title = {Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {5},
  pages = {545--557},
  doi = {10.1200/jco.24.00337}
}
Kostenlos starten →